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Nitric oxide synthases (NOSs) are classified function-
ally, based on whether calmodulin binding is Ca
21-de-
pendent (cNOS) or Ca
21-independent (iNOS). This key
dichotomy has not been defined at the molecular level.
Here we show that cNOS isoforms contain a unique
polypeptide insert in their FMN binding domains which
is not shared with iNOS or other related flavoproteins.
Previously identified autoinhibitory domains in cal-
modulin-regulated enzymes raise the possibility that
the polypeptide insert is the autoinhibitory domain of
cNOSs. Consistent with this possibility, three-dimen-
sional molecular modeling suggested that the insert
originates from a site immediately adjacent to the cal-
modulin binding sequence. Synthetic peptides derived
from the 45-amino acid insert of endothelial NOS were
found to potently inhibit binding of calmodulin and ac-
tivation of cNOS isoforms. This inhibition was associ-
ated with peptide binding to NOS, rather than free cal-
modulin, and inhibition could be reversed by increasing
calmodulin concentration. In contrast, insert-derived
peptides did not interfere with the arginine site of
cNOS, as assessed from [
3H]N
G-nitro-L-arginine binding,
nor did they potently effect iNOS activity. Limited pro-
teolysis studies showed that calmodulin’s ability to gate
electron flow through cNOSs is associated with dis-
placement of the insert polypeptide; this is the first spe-
cific calmodulin-induced change in NOS conformation
to be identified. Together, our findings strongly suggest
that the insert is an autoinhibitory control element,
docking with a site on cNOSs which impedes calmodulin
binding and enzymatic activation. The autoinhibitory
control element molecularly defines cNOSs and offers a
unique target for developing novel NOS activators and
inhibitors.
Nitric oxide is a ubiquitous cell-signaling molecule, with
protean roles in physiology and pathophysiology (1–3). Encoded
by distinct genes, mammalian NO synthases (NOSs)
1 comprise
a family of three calmodulin-dependent biopterohemoflavopro-
teins that are functionally distinguished by their modes of
regulation (4). The two constitutively expressed isoforms of
NOS (cNOSs), first identified in neuronal cells (nNOS) and
endothelial cells (eNOS), remain dormant until calcium/cal-
modulin (Ca
21/CaM) binding is actuated by transient eleva-
tions in intracellular Ca
21. This Ca
21-dependent mode of reg-
ulation provides pulses of NO for moment-to-moment
modulation of vascular tone and neurosignaling. In contrast,
activity of the immunostimulant-induced isoform of NOS
(iNOS) is Ca
21-independent, providing continuous high output
NO generation for host defense. A remarkably high affinity for
CaM, even at basally low levels of intracellular calcium, is
responsible for the Ca
21 independence of iNOS (5).
Whether a given NOS isoform binds CaM in a Ca
21-depend-
ent or -independent manner has been assumed to be a property
solely of the amino acid sequence specified by a 20–25-amino
acid CaM binding site. However, this restrictive view is chal-
lenged by findings that chimeric eNOS and nNOS, which have
had their CaM binding sequences replaced with the corre-
sponding sequence from iNOS, still require Ca
21 for full activ-
ity (6, 7). Because regulation of enzyme systems by Ca
21/CaM
typically involves displacement of an intrinsic autoinhibitory
polypeptide (8, 9), we hypothesized that the binding of Ca
21/
CaM to cNOSs may similarly trigger activation by displacing a
control element. Here we identify a multiple amino acid inser-
tion which serves as a control element unique to cNOSs and
which molecularly defines Ca
21-dependent isoforms of NOS.
EXPERIMENTAL PROCEDURES
Protein Modeling—Molecular modeling of the FMN binding module
of nitric oxide synthase isoforms was done using the Insight and Ho-
mology programs from Biosym (BIOSYM/Molecular Simulations, San
Diego, CA) running on a silicon graphics Indigo2 workstation. After
alignment of NOS sequences with homologous FMN binding proteins of
known structure (see “Results”), structurally conserved region (SCR)
boxes were created corresponding to conserved regions of secondary
structure and regions involved directly in FMN binding. These regions
were characterized by high positive scores as evaluated by Dayhoff’s
mutation matrix (10). After assignment of coordinates in the SCR
regions, the loop regions between the SCR boxes were modeled by
searching the Brookhaven protein data base. The crude model structure
was relaxed to a sterically and energetically reasonable state using the
Discover program (BIOSYM/Molecular Simulations) for molecular me-
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(to B. S. S. M.), and a grant from the Robert A. Welch Foundation (to
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@med.cornell.edu.
1 The abbreviations used are: NOS, nitric oxide synthase; cNOS,
calcium-dependent NOS, iNOS, calcium-independent NOS; eNOS, the
endothelial isoform of cNOS; nNOS, the neuronal isoform of cNOS;
CaM, calmodulin, SCR, structurally conserved region; CPR, cytochrome
P450 reductase; DTT, dithiothreitol.
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 chanics and dynamics calculations. This includes splice repair to re-
move unrealistic structural features at SCR-loop junctions, end repair
to assign reasonable structures to C-terminal and N-terminal exten-
sions, and structural optimization to remove steric overlaps and to
reduce the structure to a energetic minimum. Energy minimizations
were begun using the steepest descent method; this was replaced by
conjugate gradient method as convergence was approached.
Purification of NOS Isoforms—Rat neuronal cNOS (nNOS) and bo-
vine endothelial cNOS (eNOS) were purified from Escherichia coli har-
boring pGroELS and pCW vector expression systems for nNOS and
eNOS, as described previously (11, 12). iNOS-rich cytosol was prepared
from rat aortic smooth muscle cells, which were isolated from Fisher rat
thoracic aortae (13) and grown in 75-cm
2 culture flasks at passage
10–15. Cells were stimulated for 16 h in culture medium containing a
combination of lipopolysaccharide (30 mg/ml) and rat recombinant in-
terferon-g (50 ng/ml), washed twice with 10 ml of ice-cold phosphate-
buffered saline, and harvested with a Teflon cell scraper into an addi-
tional 10 ml of iced phosphate-buffered saline. Cell suspensions were
centrifuged at 800 3 g for 10 min, resuspended in 100 ml/75-cm
2 culture
flask of ice-cold distilled H2O containing a mixture of protease inhibi-
tors (pepstatin 10 mg/ml, leupeptin 10 mg/ml, and phenylmethylsulfonyl
fluoride 100 mM) and lysed by three cycles of freezing in liquid nitrogen
and thawing in a 37 °C water bath. Lysates were centrifuged at
100,000 3 g for 1 h, and supernatants were stored at 270 °C until use.
NOS Activity Measurement—NOS activity was measured in 96-well
microtiter plates at 25 °C based on the kinetics of NADPH consumption
or the oxidation of Fe
21-myoglobin to Fe
31-myoglobin, as described
previously (14). For NADPH consumption measurements, incubation
mixtures contained 50 mM Tris-HCl (pH 7.60), 100 mM CaCl2,1 0mM
tetrahydrobiopterin, 500 mM NADPH, 500 mML -arginine, 1 mM DTT, 1
mM calmodulin, pH 7.6, and the indicated concentration of peptide in a
final volume of 100 ml. Reactions were initiated by the addition of 20
pmol of nNOS, 10 pmol of eNOS, or 15 mg of rat iNOS-rich cytosol.
NADPH consumption was determined from the rate of decrease in A340,
measured at 15-s intervals for a period of 30 min in a kinetic microplate
spectrophotometer (Molecular Devices; Menlo Park, CA). The rate of
decline in A340 measured when NOS was omitted from incubates was
subtracted from all values. Samples in which iNOS activity was meas-
ured based on Fe
21-myoglobin oxidation were prepared as above, but
additionally contained 15 mg of rat iNOS-rich cytosol and a final con-
centration of 40 mM Fe
21-myoglobin. Preparation of Fe
21-myoglobin and
spectrophotometric measurement of its rate of oxidation to Met-myo-
globin by NO, was as described earlier (14).
125I-Calmodulin Binding Measurement—Calmodulin was labeled
with
125I to a specific activity of 25–150 mCi/g, using the Bolton-Hunter
method (15).
125I-Calmodulin binding assays were performed in tripli-
cate using 96-well microfiltration plates with GFB filter bottoms (Mil-
lipore, Bedford, MA). Before use, filters were preincubated for 1–2 min
with 100 ml of buffer containing 50 mM Tris-HCl, pH 7.6, 1 mM DTT, 100
mM CaCl2, and 0.5 mg/ml b-lactoglobulin; buffer was then removed by
vacuum filtration. Binding reactions were comprised of: 50 mM Tris-
HCl, pH 7.6, 1 mM DTT, 0.5 mg/ml b-lactoglobulin, 100 mM CaCl2,1 0mM
tetrahydrobiopterin, 1 nM
125I-CaM (2500–5000 cpm) and 1–2 pmol of
NOS in a 100-ml total volume. Samples were incubated for 15 min at
23 °C, and binding was quickly terminated by vacuum filtration. Filters
were washed twice with 100 ml of ice-cold buffer containing 50 mM
Tris-HCl, pH 7.6, and 100 mM CaCl2 and air-dried. Scintillation mixture
was added to each well (25 ml; OptiPhase SuperMix, Wallac Inc., Gaith-
ersburg, MD), and plates were counted in a Microbeta Plus liquid
scintillation counter (Wallac Inc.). Nonspecific binding was determined
in samples that additionally contained 10 mM EGTA. In studies of the
effect of inhibitory effect of peptide inhibitors on
125I-CaM binding to
NOS, blank binding was determined in the presence of peptide and
absence of NOS. Dissociation of
125I-CaM was similarly monitored in
96-well filtration plates.
125I-CaMznNOS complexes were first produced
by incubation of 2 pmol of nNOS, 1 nM of
125I-CaM, 100 mM CaCl2,1 0mM
tetrahydrobiopterin, 50 mM Tris-HCl, pH 7.6, 1 mM DTT, and 0.5 mg/ml
b-lactoglobulin for 15 min (23 °C). To initate dissociation, a 3000-fold
excess of unlabeled CaM (3 mM) was added at time 0, with or without
simultaneous addition of the indicated concentration of bovine
eNOS
607–634.
[
3H]N
GNitro-L-arginine Binding Measurement—Assays of [
3H]N
G-
nitro-L-arginine binding were performed in 96-well polyvinylidene di-
fluoride microfiltration plates (Millipore, Bedford, MA) as described
previously (16), using 5 pmol of nNOS and the indicated concentrations
of NOS-derived peptides.
Calcineurin Activity Measurement—Activity of the calmodulin-de-
pendent phosphatase calcineurin (protein phosphatase 2B) was moni-
tored in a 96-well kinetic microplate spectrophotometer at 37 °C, based
on rate of hydrolysis of the artificial substrate p-nitrophenyl phosphate
(17). Incubation mixtures contained 50 mM Tris-HCl, pH 7.6, 100 nM
bovine brain calmodulin, 40 mM p-nitrophenyl phosphate, 400 mM
CaCl2, and 0.1% 2-mercaptoethanol in a 100-ml total volume. Reactions
were initiated by the addition of 20 pmol of calcineurin, and activity was
monitored continually at A405 for 60 min at 15-s intervals. Assay blanks
additionally contained 10 mM EGTA, resulting in .90% inhibition of
activity.
Proteolysis of NOS Isoforms—Limited proteolysis was performed on
incubates containing 40 pmol of recombinant nNOS purified from sta-
bly transfected HEK-293 cells (11) or 50 pmol of recombinant eNOS
purified from E. coli (12). Samples were preincubated at room temper-
ature for 15 min in a 100-ml volume containing: 50 mM Tris, pH 7.6, 1
mM DTT, 10 mM CaM, 100 mM CaCl2, with or without 10 mM EGTA.
Proteolysis was initiated by the addition of 20 microunits of L-1-tosyl-
amido-2-phenylethyl chloromethyl ketone-immobilized trypsin (Sigma)
per pmol of NOS. Samples (25 ml) were collected after 0, 5, 10, and 20
min, and proteolysis was terminated by boiling with an equal volume of
2 3 SDS gel-loading buffer. Peptide products were resolved on an
8–16% gradient SDS-polyacrylamide gel electrophoresis and visualized
by staining with Coomassie Blue. Accurate molecular mass determina-
tion of tryptic fragments was performed by mass spectrometry at the
Rockefeller University Protein/DNA Biotechnology Center, using ma-
trix-assisted laser desorption and time of flight detection (Perseptive
Biosystems Inc., Framingham, MA). For N-terminal sequence analysis,
tryptic digests were prepared as above and subject to SDS-polyacryl-
amide gel electrophoresis, but then electrotransfered to polyvinylidene
difluoride membranes. Amino acid sequencing was performed on an
Applied Biosystems 477A protein sequencer.
Peptides—Synthetic peptides were obtained from SynPep (Dublin,
CA) and other commercial suppliers. Purity was evaluated by high
performance liquid chromatography and mass spectroscopy and ex-
ceeded 80% in all cases with typical purity '90%. Predominant impu-
rities differed from the desired products by one amino acid residue,
resulting from incompletely coupled synthesis.
Chemicals—Rat recombinant interferon-g, RPMI culture medium,
and cell culture reagents were from Life Technologies, Inc. Radioiso-
topes were from Dupont NEN, lipopolysaccharide (E. coli serotype
0111:B4), chemicals, and L-1-tosylamido-2-phenylethyl chloromethyl
ketone-immobilized trypsin were obtained from Sigma, calmodulin was
from Calbiochem, and tetrahydrobiopterin was from Schirks Laborato-
ries (Jona, Switzerland). Enzymes were purchased from Pharmacia
LKB Biotechnology, Promega, or New England Biolabs.
RESULTS AND DISCUSSION
Nitric oxide synthases are large multidomain enzymes in
which a series of gene fusion events has resulted in the incor-
poration of modules showing significant homology to smaller
ancestral proteins (18, 19). NOSs can be coarsely dissected into
an N-terminal oxygenase domain and a C-terminal reductase
domain, bridged by a canonical binding sequence for CaM (20).
Calmodulin binding initiates electron transfer between the
reductase and catalytic domains, thereby activating catalysis
(21). The oxygenase domains have binding sites for substrate
(arginine), heme, and tetrahydrobiopterin, whereas the reduc-
tase domain has binding sites for FAD, FMN, and NADPH.
Bredt et al. (22) were first to reveal the homology between
the C-terminal half of NOS and NADPH-cytochrome P450 re-
ductase (CPR), noting conserved regions corresponding to
FMN, FAD, and NADPH binding domains. The FMN-binding
modules of NOS isoforms and CPR are in turn highly homolo-
gous to the flavodoxins, which are small FMN-binding proteins
that function as electron carriers in bacteria (23). The FAD and
NADPH binding domains are closely related to chloroplast
ferredoxin-NADP
1 reductase and other related proteins.
Sequence Alignments—Five flavodoxins have been crystal-
lized and solved by x-ray diffraction (24). Three regions in these
flavodoxins are involved in binding the FMN prosthetic group;
the first of these is close to the N terminus, and is immediately
proceeded by the initial b strand of the structure. Although
only one of these FMN binding regions was identified in nNOS
by Bredt et al. (22), each of them has a corresponding homolog
The Autoinhibitory Domain of cNOSs 29770
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 in NOSs. The first step in alignment of the NOS FMN binding
domain with the flavodoxins was the identification of these
regions in each NOS isoform. This was followed by the identi-
fication of conserved secondary structural elements in NOS,
primarily by their homology to the corresponding elements in
flavodoxins by mutation matrix criteria (10).
Fig. 1 shows alignment of a select set of NOS, CPR, and
bacterial flavodoxin sequences, illustrating the conservation of
regions involved in FMN binding. It is obvious that a major
insertion of '45 amino acids has occurred in mammalian
cNOSs. A corresponding insert is also found in the FMN bind-
ing region of the cloned invertebrate cNOSs from Rhodnius
prolixus (25) and Drosophila melanogaster (26); these inserts
are somewhat larger (54–63 amino acids), but contain regions
of marked homology to mammalian cNOS inserts. Expanding
this alignment to include dozens of known flavodoxins and
related FMN-containing flavoproteins reveals that only cNOSs
exhibit such an insertion. Moreover, the corresponding region
of iNOS sequences closely resemble flavodoxin sequences but
lack an insert anywhere within the FMN binding domain.
Therefore, occurrence of the amino acid insertion correlates
with Ca
21/CaM control. This insertion represents the single
most prominent difference between cNOSs and iNOS amino
acid sequences, considered over their entire length.
The cNOS FMN module insertions are notably rich in
charged residues and have an excess of positive charge. This is
especially true of the eNOS isoform, which contains the motif
RRKRK. Considerable homology exists between the cNOS in-
sertions, particularly toward their N termini. It is also appar-
ent that some structural reorganization has taken place during
evolution, which may allow the two or three positively charged
residues (depending on species) in the nNOS equivalent of the
RRKRK region to recognize a similar binding site. The pattern
of conservation suggests that eNOS and nNOS insertions con-
tain at least two motifs.
Structural Models—The availability of solved x-ray crystal
structures for flavodoxins allows us to position the insertion in
three dimensions relative to the calmodulin binding site. Ho-
mology-based molecular models have been constructed for the
FMN binding domains of cNOSs, iNOS, and CPR, which could
be relaxed to a sterically and energetically reasonable state.
After relaxation of these FMN binding domain models, no
steric overlaps were present, and energies were approximately
2300 kcal, comparable or lower than that of reference fla-
vodoxin crystal structures.
As shown in Fig. 2 (upper left), the backbone structure of
iNOS and CPR are virtually superimposable on the backbone of
Desulfovibrio vulgaris flavodoxin, the closest solved structural
homolog of the FMN binding modules of the NOS isoforms.
2
The structure, a Rossmann fold motif (28), is a five stranded
parallel b-sheet with the FMN binding site along one edge.
Homology predicts that two aromatic residues in murine iNOS,
Phe
587 and Tyr
625, are in contact with the FMN ring system;
Tyr
625 serves as a shielding residue.
Fig. 2 (upper right) shows the corresponding backbone struc-
ture of eNOS; nNOS is extremely similar but not shown. Most
of the eNOS backbone can be superimposed on homologs shown
in Fig. 2 (upper left), with the insertion projecting from the
upper edge of the sheet opposite the FMN binding site. Struc-
turally, it corresponds to the replacement of a tight 5–10 resi-
due a 3 b loop with an '50-residue structure about one-third
the size of the entire FMN binding module. We are unable to
propose a conformation for the insertion because we lack a
solved homolog; the structure shown is merely intended to
convey relative position and size.
The CaM binding site is immediately adjacent to the N-
terminal edge of the FMN binding domain (painted white in
Fig. 2, upper left). With CaM bound, the CaM recognition site
would predictably be in a helical conformation (29, 30); steric
constraints suggest that it extends almost directly away from
the FMN binding domain. The lower panels of Fig. 2 show
models of the FMN binding domains of iNOS (left) and eNOS
(right) with CaM (yellow ribbon; based on Vorherr et al. (30))
positioned above the N-terminal strand of the FMN domain.
There are 7–8 residues between the end of the CAM recogni-
tion site proper and the start of the initial strand of the b-sheet;
2–3 residues at each end of this short linker are needed to clear
the van der Waals surfaces of CaM and the FMN domain. This
leaves 2–3 residues that are conformationally unrestricted,
and, hence, there are uncertainties about the exact position
above the b-sheet of CaM and the orientation of the axis of the
CaM recognition site. The position of CaM relative to the FMN
domain is unspecified with respect to rotations about the y axis
of Fig. 2 by available information (corresponding to the axis of
2 Recently, the crystal structure of NADPH-cytochrome P450 oxi-
doreductase has been reported at 3.0 Å resolution (27). The FMN-
binding module bears striking homology to D. vulgaris flavodoxin.
FIG.1 . Structure-based sequence
alignment of FMN binding domains of
human NADP
1-cytochrome 450 reduc-
tase (NCPR_HUMAN), bovine eNOS
(NOSE_BOVIN), rat nNOS (NOSB_
RAT), mouse iNOS (NOSM_MOUSE)
and flavodoxins from E. coli (FLAV_E-
COLI), and D. vulgaris (FLAV_DES-
VH). Complete sequences were obtained
from the Swiss Protein data base using the
given designations. Alignment was per-
formed manually by aligning the flavin
binding sequences and conserved second-
ary structural elements from flavodoxin
crystal structures as evaluated with Bio-
sym’s Homology software. The C-terminal
end of the domain ('35 residues for Desul-
fovibrio sequence) is omitted to conserve
space.
The Autoinhibitory Domain of cNOSs 29771
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 the CaM-binding helix of lower panels). It is notable that cal-
modulins (molecular mass ' 17 kDa) are larger than the entire
FMN-binding module. Although the insertion is midway
through the sequence of the FMN-binding module, in three
dimensions the model predicts it to be directly adjacent to the
CaM binding site. The model predicts also that CaM binding
would be sterically hindered by the insertion, suggesting that
the insertion can exist in more than one physiologically rele-
vant conformation.
Two aspects of this model strongly suggest that the insert
functions as a control element, 1) the correlation between Ca
21/
CaM control and the presence of the insertion and 2) the
proximity of the CaM binding site to the insertion and the
probable steric interactions which would ensue. An attractive
potential role for the insert is that of an inhibitory polypeptide
which is displaced by CaM binding. It differs from inhibitory
polypeptides common to other CaM-dependent enzymes, and
CaM itself, in its lack of acidic and hydrophobic amino acids;
this makes direct binding of the insertion to CaM sites in NOS
isoforms unlikely. Nonetheless, CaM could conceivably dis-
place the polypeptide insert from a neighboring site by binding
domain overlap or through allosteric effects.
Synthetic Polypeptide Effects on NOS Activity—Functional
significance of the putative autoinhibitory insert of cNOSs was
evaluated using a series of synthetic polypeptide fragments.
Polypeptides corresponding to promising recognition sites such
as the RRKRK motif of the eNOS insert were synthesized in
lengths ranging from 6 to 33 residues, as shown in Table I.
Both eNOS- and nNOS-derived peptide fragments were evalu-
ated; effects on NOS activity are summarized in Table II. At
concentrations of 50–100 mM, several polypeptide fragments of
the cNOS insertions profoundly inhibited eNOS and nNOS
activity. The most effective inhibitory polypeptides were from
the eNOS insertion and contained the RRKRK motif (Table II
and Fig. 3A). Human nNOS-derived polypeptides weakly in-
hibited eNOS, but were without effect on nNOS. While all
peptides were less potent on iNOS, significant inhibition was
obtained with eNOS
601–633 and eNOS
607–634. Notably, inhibi-
tion of iNOS activity by these peptides was rapid and appar-
ently complete within one minute of addition. Because CaM is
very tightly bound to iNOS and has a remarkably slow off-rate,
with little dissociation occurring even after boiling (5), inhibi-
tion probably occurs without CaM displacement.
Synthetic Polypeptide Effects on Calmodulin Binding—Over-
lap of the cNOS polypeptide insert and the CaM recognition
site, suggested from molecular modeling, implies that the in-
sert may obstruct CaM binding. If this involves “docking” of the
insert within cNOSs, synthetic homologs of the insert might
similarly bind and interfere with CaM binding. As shown in
Table II, potent inhibition of
125I-CaM binding to nNOS was
observed with insert-derived polypeptide fragments; relative
peptide potency for inhibiting CaM binding mirrored that for
blocking nNOS activation. IC50 values for eNOS-derived pep-
tide fragments ranged from 1 to 10 mM, and potency increased
as the RRKRK motif was progressively lengthened to include
up to 33 amino acids (Fig. 3B). Inhibition of nNOS activity
and CaM binding by insert-derived peptides was fully re-
versed by excess CaM (see Fig. 3, C and D, for findings with
eNOS
607–634), indicative of a competitive mode of inhibition.
Thus, the greater apparent potency of peptides for inhibiting
CaM binding versus activity, indicated in Table II, is explained
by differences in assay conditions; lower CaM concentrations
FIG.2 . Structural models of FMN
binding domains. Upper left panel, fla-
vodoxin (silver; from McMillan et al. (11)),
cytochrome P450 reductase (gold; homol-
ogy model), rat iNOS (cyan, homology
model). Upper right panel, bovine eNOS
(pink, with autoinhibitory peptide in gold;
homology model). N-terminal residues of
NOS isoform domains are depicted in
white with the CaM binding site directly
above this point. FMN is shown in space
filling representation at bottom. Central
b-sheets and flanking a-helices are visible
in all structures. Lower panels, approxi-
mate location of bound CaM (yellow, with
NOS CaM binding sequence in blue) rel-
ative to FMN binding domain (pink, with
FMN in gold space-filling rendering) of
rat iNOS (left) and bovine eNOS (right).
The Autoinhibitory Domain of cNOSs 29772
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 were used to assess binding (1 nM) versus activity (100 nM).
Inhibition of CaM binding by peptide could not be overcome by
excess Ca
21 (Fig. 3E).
Conceivably, the synthetic peptides could interfere with CaM
binding to NOS by interacting with either NOS or CaM itself.
That NOS is the actual binding target for eNOS-derived insert
peptides is indicated by several findings. First, direct binding of
peptide to
125I-CaM, quantified in the absence of NOS, was
undetectable at concentrations that inhibited .90% of CaM
binding to nNOS (data not shown). Second, the CaM-dependent
phosphatase calcineurin, which resembles cNOSs in having a
Kd for CaM of 5 nM (31), was not inhibited by concentrations of
insert-derived peptides that potently inhibit nNOS activity (see
Fig. 4). Third, eNOS-derived peptides markedly enhanced the
dissociation rate of
125I-CaM from preformed complexes with
nNOS (Fig. 3D). In this experimental setting, dissociated
125I-
CaM is prevented from reassociating with NOS by addition of
a 3,000-fold molar excess of unlabeled CaM. Thus, in order for
a synthetic eNOS-derived peptide to eject CaM from its binding
site on nNOS, it must at least transiently form a ternary
CaM-containing complex with NOS. Conceivably, this tran-
sient ternary complex could involve interactions of peptide with
CaM as well as NOS. These findings suggest that the binding
domain of the putative eNOS autoinhibitory element on nNOS
either overlaps or allosterically perturbs the CaM binding
domain.
Previously described inhibitors with demonstrated selectiv-
ity for NOS influence the arginine site in a manner that can be
detected as a loss in sites or binding affinity for the arginine
analog, [
3H]N
G-nitro-L-arginine. Thus, it is notable that the
cNOS insert peptides inhibit NOS activity and CaM binding
with a slight increase, rather than decrease, in [
3H]N
G-nitro-
L-arginine binding (Table II). Specificity of the insert peptides
is also indicated by a lack of inhibition of either NOS activity or
CaM binding with each of five synthetic peptides, 10–15 amino
acids in length, derived from sites on the FMN binding domain
of cNOSs, which are distinct from the insert polypeptide (not
shown).
Effects of Calmodulin on Exposure of the Insert—Displace-
ment of the insert peptide from an internalized binding site on
cNOSs by CaM would conceivably enhance exposure of the
insert to proteolysis. This hypothesis was tested by examining
the pattern of peptide accumulation during limited trypsinoly-
sis of both nNOS and eNOS, in the absence and presence of
bound CaM (Fig. 5).
Earlier, Sheta et al. (20) showed that of 165 possible tryptic
cleavage sites in rat nNOS, a single preferred cut site resides at
Arg
727 within the CaM binding sequence. Cutting at this site
has served as an effective means for isolation of distinct reduc-
tase and oxygenase domains. With CaM present but not bound
(due to addition of the Ca
21-chelator, EDTA; see Fig. 5A), we
similarly observe that tryptic cleavage of nNOS occurs almost
exclusively at a single site, consistent with Arg
727 within the
CaM binding site. Accordingly, we found a time-dependent
accumulation of fragments with apparent molecular masses of
77 and 85 kDa, corresponding to C-terminal reductase and
N-terminal oxygenase domains, respectively (Fig. 5A). When
CaM was permitted to bind nNOS, by omission of EDTA,
Arg
727 was protected from proteolysis, and a novel tryptic
cleavage site was revealed. Cutting at this new site yielded
fragments of apparent molecular masses of 63 and 93 kDa (Fig.
5A). Molecular mass refinement by matrix-assisted laser de-
sorption ionization spectrometry indicated the smaller frag-
ment to be 64,809 6 324 Da. This product is best explained by
cleavage at Arg
855–Lys
856, a dibasic (RK) site within the insert
peptide which predicts a C-terminal fragment of 65,071 Da.
That this fragment originates from the C terminus of nNOS is
indicated by our finding that it is the predominant trypsinoly-
sis product of the bacterial-expressed C-terminal reductase
domain (nNOS
721–1429) but is not produced by trypsinolysis of
the N-terminal oxygenase domain (nNOS
1–721) (data not
shown). Confirmation of cleavage at Lys
856 is provided by di-
rect sequence analysis of its 10 N-terminal amino acids (KSS-
GDGPDLR). In accord with our findings, a thorough analysis of
nNOS trypsinolysis, in the absence of bound CaM, indicates
that Lys
856 becomes a cut site following initial cleavage within
the CaM binding site at Arg
727 (32). Since Lys
856 is protected
from tryptic cleavage in the absence of CaM, but exposed when
CaM is bound (or the CaM binding site is severed), we conclude
that CaM displaces the FMN domain insert peptide of nNOS.
A similar conclusion is drawn from study of eNOS fragmen-
tation after limited trypsinolysis. When CaM is not bound,
tryptic cleavage of eNOS yields four principal peptides of nom-
inal molecular masses of 57, 60, 68, and 77 kDa (Fig. 5B). This
pattern is rationalized by cleavage at Arg
518 within the CaM
TABLE I
Peptide derivation and composition
Sequence and derivation of polypeptides excerpted from the insert in
the FMN binding domain of cNOSs and tested for effects on
NOS activity and binding.
Designation Derivation
a Sequence
eNOS628–633 b WRRKRK
eNOS626–636 b SSWRRKRKESS
nNOS835–845 h QEERKSYKVRF
eNOS604–615 h RPEQHKSYKIRF
eNOS601–633 b SSPRPEQHKSYKIRFNSVSCSDPLVSSWRRKRK
eNOS607–634 b QHKSYKIRFNSVSCSDPLVSSWRRKRKE
nNOS851–864 r SDSRKSSGDGPDLR
nNOS835–864 h QEERKSYKVRFNSVSSYSDSQKSSGDGPDL
a h, human; b, bovine, r, rat.
TABLE II
The FMN binding domain insert of cNOSs: effect of peptide fragments on NOS activity and ligand binding
Peptide
NOS activity
a Ligand Binding to nNOS
b
nNOS eNOS iNOS [
3H]-NNA
125I-CaM
mg/ml (mM) % of control
eNOS628–633 100 (107.0) 11.0 6 3.3 24.0 6 2.8 91.1 6 5.7 91.7 6 5.1 6.7 6 3.6
eNOS626–636 100 (71.2) 19.1 6 0.9 27.7 6 2.0 92.1 6 1.3 120.7 6 12.7 0.0 6 0.5
nNOS835–845 100 (68.1) 102.0 6 2.1 93.6 6 2.3 101.1 6 3.7 118.9 6 4.1 82.7 6 1.1
eNOS604–615 100 (63.0) 54.5 6 1.8 80.5 6 2.0 99.7 6 5.7 115.0 6 8.6 24.7 6 2.2
eNOS601–633 300 (76.0) 30.4 6 1.7 57.2 6 7.5 62.2 6 2.8 116.3 6 1.9 0.0 6 7.4
eNOS607–634 300 (87.7) 28.2 6 0.9 40.2 6 4.0 64.3 6 3.2 122.4 6 1.0 0.0 6 4.8
nNOS851–864 100 (72.0) 98.4 6 1.9 102.6 6 4.1 99.7 6 2.8 119.2 6 3.4 89.2 6 6.2
nNOS835–864 300 (84.8) 103.0 6 1.3 80.2 6 3.8 84.1 6 3.5 95.7 6 4.7 82.7 6 1.1
a NOS activity measurements were performed using purified recombinant nNOS and eNOS, or native iNOS. Values are means 6 S.E. of
triplicate determinations.
b Radioligand binding was performed after incubation of 1–2 pmol of NOS for 15 min at 23 °C with either
125I-calmodulin (1 nM)o r
[
3H]N
G-nitro-L-arginine (NNA) (200 pM) and the indicated peptides. Values are means 6 S.E. of triplicate determinations.
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 binding site (eNOS
1–518 5 56,877 Da, eNOS
519–1204 5 76,308
Da) and at a second site, likely to be Lys
545, which resides
between the CaM binding site and insert peptide (eNOS
1–545 5
59,916; eNOS
546–1204 5 73,270). Exposure of Lys
545 and prox-
imity to the CaM binding site is predicted in the model shown
in Fig. 2; this site appears to be within a helix-turn transition
at the edge of the b-sheet distant from the FMN binding site.
Lack of cleavage in nNOS at the site homologous to eNOS
Lys
545 may be explained by the presence of a single basic
residue, while eNOS contains paired basic residues (RK). In
FIG.3 .Influence of eNOS-insert peptides on NOS activity and CaM binding. Panel A, NOS activity is inhibited by eNOS
601–633. nNOS
activity was measured kinetically, based on the rate of NADPH consumption; iNOS activity was measured as the rate of NO formation, based on
Fe
21-myoglobin oxidation. Activities are expressed as percent of control samples in which eNOS
601–633 was omitted. Panel B,
125I-CaM binding to
nNOS is inhibited by eNOS insert-derived peptides. Specific inhibition of
125I-CaM binding to nNOS was assessed as a function of concentration
of added peptide in a 96-well microfiltration plate assay. Panel C, Inhibition of nNOS activity by eNOS
607–634 is reversed by excess CaM. Activity
was measured as percent NADPH consumption rate in the presence of a maximally effective concentration of CaM (0.1 mM), prior to addition of
peptide. Note that inhibition of nNOS activity was greater than 80% after addition of 100 mM eNOS
607–634, but restored to the control level by
addition of 10-fold more CaM (solid bar). Panel D, Inhibition of
125I-CaM binding to nNOS by eNOS
607–634 is competitive with [CaM].
125I-CaM
binding assays were performed as for panel B, over a range of CaM concentrations in the absence (control) or presence of peptide. Panel E,
inhibition of CaM binding to nNOS by eNOS
607–634 is not reversed by Ca
21 excess.
125I-CaM binding assays were performed as for panel B, except
that CaCl2 concentrations were varied. “Zero” Ca
21 (,1n M) was achieved by inclusion of 10 mM EGTA. Panel F, dissociation of
125I-CaM from
nNOS is accelerated by eNOS
607–634.
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 any event, binding of CaM simplifies this cleavage pattern by
providing a single dominant cut site. Neglecting the intact
proteins and the 10-kDa band from small unresolved fragments
of eNOS, only two strong bands are visible at 60 and 65 kDa.
These are predicted by cleavage of the molecule within the
pentabasic RRKRK motif in the insert peptide at residue
Lys
632. Thus, cleavage at Lys
632 (with additional cleavage of
the N-terminal fragment at Lys
545) produces fragments of
59,916 Da (eNOS
1–545) and 63,251 Da (eNOS
633–1024). Align-
ment reveals close correspondence between Lys
632 of eNOS and
Lys
856 of nNOS (see Fig. 1), suggesting that CaM binding
similarly displaces the insert peptide in each cNOS isoform.
To summarize, CaM binding not only protects the CaM bind-
ing site from degradation by trypsin, but exposes cleavage sites
on both nNOS and eNOS, which are otherwise inaccessible. A
preponderance of evidence points to the clusters of basic resi-
dues in the FMN domain insert as the trypsin cleavage sites
which are exposed by CaM binding. Exposure of cryptic sites by
CaM binding could occur by an allosteric mechanism, or by
displacement through binding domain overlap. CaM-driven
movement of the insert strongly suggests a switch function for
activation of NO synthesis.
Mechanism of NOS Control—Herein we have shown that
cNOSs possess a polypeptide insert in their FMN binding mod-
ules that is 1) unique to NOS isoforms which are regulated by
transient CaM binding; 2) positioned adjacent to the CaM
binding domain; 3) an impediment to CaM binding and hence,
NOS activation; and 4) displaced when CaM binding does oc-
cur. Together, these results strongly imply that the insertion in
cNOSs is an autoinhibitory control element. We propose that
inhibition of NOS by the insert requires occupancy of key sites
on cNOS. CaM binding displaces the insert, thus activating
cNOS catalysis by “disinhibition.” Close proximity of the inhib-
itory polypeptide to its cognate binding site(s) on cNOSs would
result in an exceedingly high local concentration, thus favoring
the bound/inhibited state in the absence of CaM. The detection
of basal activity with either purified eNOS or nNOS, in the
simultaneous presence of EGTA and absence of CaM ('5% of
maximal),
3,4 may arise from a low steady-state concentration of
the disinhibited cNOS conformer.
The control mechanism requires that CaM displace the in-
sert upon binding to cNOS; this should translate into a reduced
affinity for CaM. Reciprocally, absence of the insert from iNOS
would preclude the otherwise expected steric hindrance to CaM
binding, contributing to the much tighter binding of CaM at
low levels of Ca
21. Studies of polypeptides, corresponding to
the putative CaM binding sites on eNOS and iNOS, and of
chimeras in which the putative CaM binding sequence of one
NOS isoform is substituted with the corresponding portion of
another, have indicated that affinity and calcium-dependence
of CaM binding is provided by elements on NOS in addition to
the recognized CaM binding sequence itself (6, 7). These results
have been interpreted as indicating the presence of an auxil-
iary CaM binding region on iNOS that augments binding. An
alternative explanation, raised by our findings, is that the
absence of the autoinhibitory polypeptide from iNOS contrib-
utes to enhanced CaM affinity at low Ca
21 levels. We hypoth-
esize that iNOS evolved from an ancestral cNOS-like protein by
loss of the inhibitory peptide; nonetheless, vestigial regulatory
sites are suggested by a weak inhibition of activity in the pres-
ence of synthetic fragments of the eNOS inhibitory peptide. The
CaM binding sites on iNOS and cNOS are apparently related to
a similar basic region near the N terminus of CPR, and may have
evolved from such a region in a common ancestral protein.
Our data suggest that binding of the inhibitory peptide may
involve at least two regions. At least one recognition site binds
the RRKRK motif. A second possible site might recognize se-
quences such as EERKSYKVRF and EQHKSYKIRF that occur
in the N-terminal half of the eNOS and nNOS insertions;
peptides that lack RRKRK but contain these sequences weakly
inhibit NOS activity and CaM binding. Some similarity be-
tween the first and second halves of the insertion can be readily
noted by comparing the sequences of peptide eNOS
628–633 and
eNOS
626–636 with those of nNOS
835–845 and eNOS
604–615. The
insert peptide also contains an abundance of serine and thre-
onine residues which provide potential sites for phosphoryla-
tion (12/45 residues in the bovine eNOS insert). We speculate
that phosphorylation/dephosphorylation may influence the af-
finity of insert peptides for binding cognate sites on cNOSs and
hence, impact on parameters of NOS activation and/or deacti-
vation. In this regard, it is notable that skeletal muscle pos-
sesses an nNOS splice variant in which the insert peptide is
expanded by 36 residues (33), providing additional sites for
possible cell-type specific modification.
Many important questions remain to be answered. The loca-
tion and identity of the sites of interaction with the inhibitory
polypeptide on the surface of the enzyme are not known. Re-
gions of interaction could include the flanking surface loops of
3 Q. Liu and S. Gross, unpublished observation.
4 P. Martasek and B. S. S. Masters, unpublished observation.
FIG.4 .CaM-stimulated nNOS activ-
ity, but not calcineurin activity, is in-
hibited by the FMN insert-derived
peptide eNOS607–633. Kinetic assays
were performed as described under “Ex-
perimental Procedures”; bars represent
means of triplicate determinations 6
S.E., performed in the absence and pres-
ence of the indicated peptide concentra-
tions. Reaction blanks were performed in
the presence of 10 mM EGTA to define
CaM-dependent activity of nNOS and cal-
cineurin. In both cases, EGTA reduced
activity to a level .10% of that measured
in the absence of calcium chelator.
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 the FMN domain, bound CaM, and additional more distant
sites. In particular, a site on the oxygenase domain consisting
of an array of acidic groups could serve as a binding site for the
basic regions on the inhibitory polypeptide insert which stabi-
lizes the inhibited conformation of cNOS.
While it seems clear that CaM binding and activation of
cNOS is associated with displacement of the inhibitory
polypeptide, it is not known how the presence of the polypep-
tide in its initial conformation inhibits electron transfer. An
obvious mechanism would involve interference by the inhibi-
tory polypeptide with interactions between the oxygenase and
reductase domains or flavin subdomains, stabilizing a confor-
mation which does not support rapid electron transfer. Such
interference could involve changes in either heme/FMN or
FMN/FAD distances driven by domain realignment. Intramo-
lecular electron transfer rates are often determined by the
ability of electrons to tunnel, and therefore fall off exponen-
tially with distance at roughly an order of magnitude per bond
length (34); thus, a small increase in interdomain distance could
produce a large reduction in electron flux. Displacement of the
inhibitory peptide may not be the only mechanism by which CaM
binding stabilizes the activate conformation of cNOSs, inasmuch
as CaM removal results in inactivation of iNOS.
In conclusion, we have identified a novel control element in
cNOSs which will serve as a prototype for the development of
potent peptide inhibitors. The exposure of tryptic cleavage sites
in this element represents the first demonstration of a specific
CaM-induced conformational change in NOS and may be a
hallmark of the active conformer of NOS. Abu-Soud and Stuehr
(21) pointed out that the use of CaM to control electron transfer
is unique to cNOS. A more fundamental difference between
cNOS and other CaM-regulated proteins is the lack of a CaM
analog within the cNOS inhibitory peptide. Ultimately, cNOS
may not be unique in this regard; it may presage the identifi-
cation of other CaM regulated systems in which the CaM/
inhibitor interaction is mediated through binding domain over-
lap or allosteric effects, rather than competition for a common
recognition site.
Acknowledgments—The encouragement and support of Joe DeAngelo
and APEX Biosciences Inc. are responsible for the pilot studies that
brought this investigation to fruition.
FIG.5 .SDS-polyacrylamide gel electrophoresis showing the products of limited tryptic digestion of cNOSs. Trypsinolysis of nNOS
(panel A) and eNOS (panel B) was performed for the indicated duration in the absence (1EDTA) or presence (2EDTA) of bound CaM. Protein bands
at 160, 133, and 17 kDa correspond to uncut nNOS, eNOS, and CaM, respectively. Results indicate that a preferred tryptic cleavage site resides
within the CaM binding sequence of cNOSs, however, when this site is masked by bound CaM, a novel tryptic cleavage is revealed within the FMN
domain polypeptide insert. Panel A shows the progressive formation from nNOS of 75- and 85-kDa fragments in the absence of bound CaM (lanes
2–5), and the accumulation of two alternative fragments of 63 and 93 kDa when CaM is bound (lanes 6–9). Panel B shows the corresponding
experiment with eNOS giving a more complicated tryptic cleavage pattern in the absence of bound CaM (lane 6–9) that is simplified to two major
fragments of 60 and 65 kDa when CaM is bound (lanes 2–5). See text for detailed interpretation of cleavage sites.
The Autoinhibitory Domain of cNOSs 29776
 
b
y
 
o
n
 
S
e
p
t
e
m
b
e
r
 
1
5
,
 
2
0
0
6
 
w
w
w
.
j
b
c
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 REFERENCES
1. Nathan, C., and Xie, Q. W. (1994) Cell 78, 915–918
2. Ignarro, L. J. (1990) Annu. Rev. Pharmacol. Toxicol. 30, 535–560
3. Moncada, S., Palmer, R. M., and Higgs, E. A. (1989) Biochem. Pharmacol. 38,
1709–1715
4. Nathan, C., and Xie, Q. W. (1994) J. Biol. Chem. 269, 13725–13728
5. Cho, H. J., Xie, Q. W., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee,
T. D., and Nathan, C. (1992) J. Exp. Med. 176, 599–604
6. Venema, R. C., Sayegh, H. S., Kent, J. D., and Harrison, D. G. (1996) J. Biol.
Chem. 271, 6435–6440
7. Ruan, J., Xie, Q., Hutchinson, N., Cho, H., Wolfe, G. C., and Nathan, C. (1996)
J. Biol. Chem. 271, 22679–22686
8. Jarrett, H. W., and Madhavan, R. (1991) J. Biol. Chem. 266, 362–371
9. Brickey, D. A., Bann, J. G., Fong, Y. L., Perrino, L., Brennan, R. G., and
Soderling, T. R. (1994) J. Biol. Chem. 269, 29047–29054
10. Dayhoff, M. O., Hunt, W. C., and Hunt, L. T. (1983) Methods Enzymol. 91,
524–545
11. McMillan, K., Bredt, D. S., Hirsch, D. J., Snyder, S. H., Clark, J. E., and
Masters, B. S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11141–11145
12. Martasek, P., Liu, Q., Liu, J., Roman, L. J., Gross, S. S., Sessa, W. C., and
Masters, B. S. (1996) Biochem. Biophys. Res. Commun. 219, 359–365
13. Gross, S. S., and Levi, R. (1992) J. Biol. Chem. 267, 25722–25729
14. Gross, S. S. (1996) Methods Enzymol. 268, 159–168
15. Bolton, A. E., and Hunter, W. M. (1973) Biochem. J. 133, 529–539
16. Nishimura, J. S., Martasek, P., McMillan, K., Salerno, J., Liu, Q., Gross, S. S.,
and Masters, B. S. (1995) Biochem. Biophys. Res. Commun. 210, 288–294
17. Takai, A., and Mieskes, G. (1991) Biochem. J. 275, 233–239
18. Masters, B. S., McMillan, K., Sheta, E. A., Nishimura, J. S., Roman, L. J., and
Martasek, P. (1996) FASEB J. 10, 552–558
19. Liu, Q., and Gross, S. S. (1996) Methods Enzymol. 268, 311–324
20. Sheta, E. A., McMillan, K., and Masters, B. S. (1994) J. Biol. Chem. 269,
15147–15153
21. Abu-Soud, H. M., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,
10769–10772
22. Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and
Snyder, S. H. (1991) Nature 351, 714–718
23. Porter, T. D. (1991) Trends Biochem. Sci. 16, 154–158
24. Watenpaugh, K. D., Sieker, L. C., and Jensen, L. H. (1973) Proc. Natl. Acad.
Sci. U. S. A. 70, 3857–3860
25. Yuda, M. (1996) GenBank
TM accession no. U59389
26. Regulski, M., and Tully, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9072–9076
27. Kim, J.-J., Wang, M., Roberts, D. L., Paschke, R., Shea, T., and Masters,
B. S. S. (1996) in Flavins and Flavoproteins (Stevenson, K. J., ed)
pp. 455–462, University of Calgary Press, Calgary, Alberta, Canada
28. Rossmann, M. G., Moras, D., and Olsen, K. W. (1974) Nature 250, 194–199
29. O’Neil, K. T., and De Grado, W. F. (1990) Trends Biochem. Sci. 15, 59–64
30. Vorherr, T., Knopfel, L., Hofmann, F., Mollner, S., Pfeuffer, T., and Carafoli, E.
(1993) Biochemistry 32, 6081–6088
31. Imparl, J. M., Senshu, T., and Graves, D. J. (1995) Arch. Biochem. Biophys.
318, 370–377
32. Lowe, P. N., Smith, D., Stammers, D. K., Riveros-Moreno, V., Moncada, S.,
Charles, I., and Boyhan, A. (1996) Biochem. J. 314, 55–62
33. Silvagno, F., Xia, H., and Bredt, D. S. (1996) J. Biol. Chem. 271, 11204–11208
34. Moser, C. C., Keske, J. M., Warncke, K., Farid, R. S., and Dutton, P. L. (1992)
Nature 355, 796–802
The Autoinhibitory Domain of cNOSs 29777
 
b
y
 
o
n
 
S
e
p
t
e
m
b
e
r
 
1
5
,
 
2
0
0
6
 
w
w
w
.
j
b
c
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 